Vectura Group

Vectura Group

Vectura Group Socially Speaking

Vectura Group News, Fundamentals and Discussion on:

Interactive Investor | Financial Times | ADVFN | Motley Fool | Proactive Investors
Ayondo
Ayondo

Vectura Group on Social Media


Vectura Group RNS, News & Media


Headline
21 Mar 2017
News - Vectura reports wider loss but revenue jumps after Skyepharma merger from Proactive Investors
21 Mar 2017
RNS press release - Vectura Group Preliminary Results from Proactive Investors
9 Mar 2017
RNS press release - Director/PDMR Share Dealing from Proactive Investors
6 Mar 2017
RNS press release - Board Change from Proactive Investors
16 Feb 2017
RNS press release - Vectura achieves ?9 million royalty cap from Proactive Investors
15 Feb 2017
RNS press release - Notice of Results from Proactive Investors
9 Feb 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
1 Feb 2017
RNS press release - Holding(s) in Company from Proactive Investors
1 Feb 2017
RNS press release - VOTING RIGHTS AND CAPITAL from Proactive Investors
25 Jan 2017
RNS press release - Seebri/ Ultibro Breezhaler 2016 sales update from Proactive Investors
24 Jan 2017
RNS press release - FDA approves IND for Vecturas VR647 from Proactive Investors
18 Jan 2017
RNS press release - Holdings in Company from Proactive Investors
11 Jan 2017
RNS press release - Pre-close update from Proactive Investors
10 Jan 2017
RNS press release - Vectura to present at the J.P. Morgan Conference from Proactive Investors
3 Jan 2017
RNS press release - Total Voting Rights from Proactive Investors
29 Dec 2016
RNS press release - Director/PDMR Shareholding from Proactive Investors
23 Dec 2016
News - Asthma firm Vectura gets a pre-Christmas boost from second piece of positive pipeline news in two days from Proactive Investors
23 Dec 2016
RNS press release - Global development programme with Mundipharma from Proactive Investors
23 Dec 2016
RNS press release - Appointment of Joint Broker from Proactive Investors
22 Dec 2016
RNS press release - Vectura announces VR876 Regulatory Approval from Proactive Investors
21 Dec 2016
RNS press release - Licensing agreement for Utibron/Seebri in the US from Proactive Investors
8 Dec 2016
RNS press release - Ultibro Breezhaler improved lung function from Proactive Investors
1 Dec 2016
RNS press release - Total Voting Rights from Proactive Investors
23 Nov 2016
RNS press release - Interim Results from Proactive Investors
22 Nov 2016
RNS press release - Further Collaboration with Hikma from Proactive Investors
15 Nov 2016
RNS press release - Additional Listing from Proactive Investors
3 Nov 2016
RNS press release - Total Voting Rights and Capital from Proactive Investors
19 Oct 2016
RNS press release - BLOCK LISTING RETURN from Proactive Investors
12 Oct 2016
RNS press release - Notice of Interim Results from Proactive Investors
3 Oct 2016
RNS press release - Director/PDMR Shareholding from Proactive Investors
3 Oct 2016
RNS press release - Total Voting Rights and Capital from Proactive Investors
30 Sep 2016
RNS press release - Director/PDMR Shareholding from Proactive Investors
28 Sep 2016
RNS press release - Director/PDMR Shareholding from Proactive Investors
27 Sep 2016
RNS press release - Director/PDMR Shareholding from Proactive Investors
27 Sep 2016
RNS press release - Director/PDMR Shareholding from Proactive Investors
23 Sep 2016
RNS press release - Director/PDMR Shareholding from Proactive Investors
7 Sep 2016
RNS press release - Result of AGM from Proactive Investors
7 Sep 2016
News - This unfancied drug stock has the potential to soar from Proactive Investors
7 Sep 2016
RNS press release - AGM trading update from Proactive Investors
5 Sep 2016
RNS press release - Product Update - Ultibro from Proactive Investors
1 Sep 2016
RNS press release - Total Voting Rights and Capital from Proactive Investors
31 Aug 2016
RNS press release - Product Update - AirFluSal from Proactive Investors
30 Aug 2016
RNS press release - Portfolio Update from Proactive Investors
5 Aug 2016
RNS press release - US$8 million Exparel from Proactive Investors
2 Aug 2016
RNS press release - Director/PDMR Shareholding from Proactive Investors
1 Aug 2016
RNS press release - Total Voting Rights and Capital from Proactive Investors
27 Jul 2016
RNS press release - Vectura initiates legal proceedings against GSK from Proactive Investors
22 Jul 2016
RNS press release - Change of accounting reference date from Proactive Investors
13 Jul 2016
RNS press release - Holding(s) in Company from Proactive Investors

Vectura Group 3 Month Chart


Vectura Group Discussion on Interactive Investor

Could our C.E.O, buy shares each month ? by d gaser

  Fri, 24 Mar 2017 12:22:00 GMT

Hi Andy unfortunately Since Susan left this company, The only thing I have E Mailed V.E.C about was the J.V . I have never asked any questions relating to Board members pay or share's but maybe I should .
I just wish some members of this BOD were more like the CEO of O.X.B. When he was offered the job he made it clear that as the C.E.O he should back his company,and he does that every month by spending one third of his salary on buying O.X.B shares on the open market.
Now that to me is some thing this CEO could copy
BE HAPPY
Dave


By d gaser

Re: I.C. view. by Andy Reilly

  Wed, 22 Mar 2017 17:34:00 GMT

Matal - good that IC have a Buy Rec on VEC, but they dont seem to appreciate how the market works. VEC was a tad toppy, and pulled back a bit today, but (HOPEFULLY) the good times will continue to roll at VEC, and it wont be long before the rise continues - a bit of consolidation isnt a bad thing at all! All the Best to holders - AR

By Andy Reilly

I.C. view. by Matal

  Tue, 21 Mar 2017 19:48:00 GMT

New-look Vectura impresses the market

Full-year results from respiratory specialist Vectura (VEC) aren't easy to digest. Not only did the group complete a significant merger with SkyePharma in 2016, it also changed its financial year-end. But like-for-like numbers suggest the picture is largely positive. Total group revenue in the nine months to December 2016 rose 9 per cent to £142m, although extra research and development costs relating to the original Vectura business sent group adjusted cash profits down 13 per cent to £43.4m.

Vectura and SkyePharma both develop inhaled respiratory products for large pharma partners and make money from royalty and milestone payments when those products are sold. Combined, the group has a portfolio of seven products, which together made over $2bn of in-market sales in 2016 and generated 62 per cent of Vectura's total revenue in the reported period.

The remaining revenues are milestone payments from the drugs and devices being developed with partners. For example, clinical approval of an unbranded version of asthma drug Advair earned Vectura a $10m fee from its partner Hikma (HIK) in April.

Broker Numis expects double-digit cash profit growth from 2017 to 2020 as the full benefits and £10m annual savings from the merger come through. But FY2017 adjusted EPS is only expected to rise by 0.1p to 5.8p as exceptional costs remain.

IC VIEW:
SkyePharma is highly cash generative, while Vectura has a big new drugs pipeline. Together we think this group could be an impressive disrupter in the vast respiratory pharma market. Buy.
Last IC View: Buy, 151p, 23 Nov 2016

LINK


By Matal

Re: Great set of accounts revenue up 76%... by Andy Reilly

  Tue, 21 Mar 2017 17:41:00 GMT

dg - I am sure you have written to the BoD, BUT, just in case you haven't - do please write and tell them to buy shares in VEC, and align their interest with shareholders. ATB AR

By Andy Reilly

Re: Great set of accounts revenue up 76%... by dave297

  Tue, 21 Mar 2017 13:32:00 GMT

I agree entirely Dave, with the exception of a settlement with GSK which is set to be a footnote in our accounts for almost 2 years, unless resolved before the court case.
I came to Vec via SKP & one thing that really hacked me off last year was the disposal by our FD of a sizeable number of shares ( a modest number of which he subsequently repurchased).
I may sound like an old record ( vinyl) but I would love to see him & the rest of our Board spend some of their hard earned but substantial packages on acquiring a meaningful number of shares in the market.If they believe in our potential & particularly from Japan & our generic collaborations they should allign their interests more with ours


By dave297

Re: Great set of accounts revenue up 76% to ... by d gaser

  Tue, 21 Mar 2017 13:19:00 GMT

I apologise for the lead in my last post ,it appears I had not removed certain sentences act, before posting.It should have read as follows (I hope this is right )
.
Excellent set of accounts as far as I can see ,we still have more growth to come soon with especialy from the collaboration with Hikma for a generic Advair Diskus® ,We also have the Chinese J.V to look forward to in 2017 , Kinnovata was established several years ago at low cost to us ,it was agree that several of our products will be produced in china, for the Chinese market,The final capitalisation of the joint venture is expected to be concluded during 2017 which will bring growth, and a good return to our bottom line .There is so much in this years accounts that it make it impossible to pick out specifics ,the accounts make excellent reading so the best way is to let you read them your selfs
BE HAPPY
DAVE
www.iii.co.uk/research/LSE:VEC/news/item/2308374/vectura-group-preliminary-results?context=LSE:VEC


By d gaser

Great set of accounts revenue up 76% to £126.5m by d gaser

  Tue, 21 Mar 2017 12:19:00 GMT

Excellent set of accounts as far as I can see ,we still have more growth to come growth to come soon with collaboration with Hikma for a generic Advair Diskus® ,We also have the Chinese J.V to look forward to, Kinnovata was established to create several years ago at low cost to bring several of our products to the Chinese market,The final capitalisation of the joint venture is expected to be concluded during 2017 which will bring growth and good returns to our bottom line .There is so much in this years accounts that it make it impossible to pick out specifics ,the accounts make excellent reading so the best way is to let you read them your selfs
BE HAPPY
DAVE

07:00:11 +00:00: Vectura Group Preliminary Results
RNS Number : 0414A
Vectura Group plc
21 March 2017


Vectura Group plc

Preliminary Results

Strong business performance in a transformational year with positive outlook for 2017

Chippenham, UK - 21 March 2017: Vectura Group plc (LSE: VEC) ("Vectura", "the Group", "the Company"), an industry-leading device and formulation business for inhaled airways products, today announces its preliminary results for the nine-month period ended 31 December 2016.
Financial Highlights

Strong financial results from a broadened portfolio of on-market products. Excluding milestones and other non-recurring sources of revenue, nine-month proforma[4] revenue growth of 26.2% and proforma[4] EBITDA[2] growth of 57.4% highlights the robust underlying performance of the business.

Reported Proforma[4] based on recurring revenue[1]
9 months ended
31 December 2016* 12 months ended
31 March
2016 Change 9 months ended
31 December 2016 9 months ended
31 December 2015 Change
Income statement
Revenue £126.5m £72.0m 75.7% £115.6m £91.6m 26.2%
Recurring revenue%[1] 80.1% 59.6% +20.5 ppts
EBITDA[2] £34.1m £23.2m 47.0% £17.0m £10.8m 57.4%
(Loss)/Profit before tax (£40.1m) (£1.9m) (2011.0%)
Basic EPS (5.3p) 1.2p (541.6%)
Basic EBITDA per share[2] 5.6p 5.7p (1.8%)

•Revenue up 76.0% to £126.5m (2015/16: £72.0m)
o Continued momentum from seven recently launched inhaled products with in-market net sales for the year to 31 December 2016 growing 81% to over $2.0bn[1]
o Reported performance also benefits from the addition of Skyepharma following the merger on 10 June 2016
•EBITDA growth of 47.0% to £34.1m reflecting robust underlying performance
•Revenue from recurring[1] sources now accounts for 80.1% of total revenue (2015/16: 59.6%)
•Loss before taxation of £40.1m compared to £1.9m in the prior period due to a higher amortisation charge of £64.0m (2015/16: £18.8m) and exceptional items of £9.4m (2015/16: £5.6m) driven by the merger
•Year-end cash of £92.5m with strong operating inflows of £28.2m offset by merger related outflows






Operational highlights

Significant growth across marketed products
•Strong flutiform® demand and product supply volumes in calendar year 2016 at record levels with good progress on capacity expansion initiatives
•Net sales of Ultibro® Breezhaler® grew 37% over the period, benefiting from FLAME data

Developments across our novel partnered pipeline
•Validation of FOX® smart nebuliser device
o First EU regulatory progress enabling commercialisation (VR876, partnered with Bayer)
o Ablynx exercised option for continued development of their RSV programme ALX-0171 (VR465) in hospitalised infants triggering a milestone for the Group of €1.5m. Phase IIb study initiated with results expected in H2 2018
•&


By d gaser

Re: Chart starting to look good by Andy Reilly

  Tue, 21 Mar 2017 12:10:00 GMT

cb - I don't always like the 'market's view' BUT it is usually fatal to fight it. While the loss is not nice, I feel that the market is much more focused on future developments - lets hope they don't let PI's down! Best of luck all - AR

By Andy Reilly

Re: Chart starting to look good by cider boyz

  Tue, 21 Mar 2017 10:57:00 GMT

I guess I was a bit lucky that there were no substantial skeletons in the results, but so far buy looks timed well. Whilst I accept AR is right that its seen a big upswing since £1.30 days the 50/200 EMA looked too good to ignore.

By cider boyz

Re: Positive? by dave297

  Tue, 21 Mar 2017 08:32:00 GMT

Broadly positive & lots of potential which should result in our being a substantially bigger company,if we remain independent, a few years down the line.Disappointing to see a Court date of Dec 18 set for our litigation V GSK & while there is scope for a compromise settlement it is likely to be one of those background scenarios which will remain hanging over us -although our SP ,hopefully, now reflects no further income from this source so any victory would be a bonus.
Good to see our JV in China is likely to come to fruition soon& Flutiform & Exparel seem to be doingvery well with scope for further expansion.
Interesting to see what anaysts/brokers have to say after the 9.30 presentation & hopefully our SP will consolidate at this higher level, pending further (good) news as the year unfolds.
a firm hold for me with neither plans to sell or buy.


By dave297

Positive? by Chicken Lips

  Tue, 21 Mar 2017 07:35:00 GMT

Was liking this until I read the £40 million loss bit:

Vectura has posted a pretax loss of £40.1m for the nine months to Dec. 31, 2016, down from the loss of £1.9m for the 12 months to March 31, 2016.

Apart from the shorter time period, the result was impacted by £64.0m for the amortisation of intangibles, versus £18.8m a year earlier.

CL


By Chicken Lips

Re: Chart starting to look good by dave297

  Mon, 20 Mar 2017 15:59:00 GMT

The Results tomorrow are known & it is the outlook statement which interests me together with news of progress in respect of any of our new prospective products/deals.A strong outlook statement together with some long awaited good news could see us higher but i am very mindful of the converse also being true.

By dave297

Re: Chart starting to look good by Andy Reilly

  Mon, 20 Mar 2017 15:12:00 GMT

cb - thats quite some rise from the Jan 30th low (129p) - they say stocks can go up as well as down, but to me that is sentiment for you! Congrats for your buying low approach - hopefully you positive view of things VEC will be confirmed some more!

I feel relaxed abut holding VEC, and the 50 day EMA looks ready to cross ABOVE the 200 day EMA, and more upside looks very possible to me, but she is getting a tad toppy for now, so there may well be a bit of consolidation soon. AR


By Andy Reilly

Chart starting to look good by cider boyz

  Mon, 20 Mar 2017 10:08:00 GMT

Have topped up. Feeling positive about this.... wanted to top up about ten days ago but messed up! a little run to £1.70 would be nice.

By cider boyz

Important and positive by Ambiorix1

  Fri, 17 Mar 2017 06:33:00 GMT

March 16, 2017 (GLOBE NEWSWIRE) -- Trinity Health, one of the largest hospital systems in the nation, and Pacira Pharmaceuticals announced they will collaborate to develop an alternative approach to opioids for pain management.
This collaboration intends to demonstrate the way health care systems and the pharmaceutical industry can work together to improve patient care and address a serious global problem that affects the health of individuals as well as communities.
In collaboration, Trinity Health and Pacira will work to improve the overall patient-recovery experience and decrease the threat of long-term opioid risks which include misuse, abuse, and addiction. In doing so, they will also improve the economics of acute care and create new procedure-specific enhanced recovery and pain protocols that, when appropriate, will include using less risky pharmaceutical alternatives to opioids. Together, the organizations will also develop both physician- and patient-facing educational materials and generate quality improvement data that tracks their successes and progress reducing the use of opioids for pain management. This data will also guide next steps in developing and testing other protocols and products.
“The health care industry must strive to eliminate painkiller addiction and its often tragic endings," said Paul Conlon, Pharm.D, J.D., and senior vice president of Clinical Quality and Patient Safety for Trinity Health. "We are pleased to be working with Pacira to develop a more people-centered approach for pain management across the many diverse communities we serve."
Under the terms of the collaborative agreement, Trinity Health and Pacira teams will identify patient populations who would most benefit from opioid minimization strategies in hospitals. They will then develop protocols and training for procedure-specific enhanced recovery. Each approach will aim to reduce or replace opioids that are commonly used to manage postsurgical pain. 
“We are excited and proud to collaborate with Trinity Health on this joint commitment to reducing reliance on opioids as the first line of defense for managing acute pain,” said Dave Stack, chairman and chief executive officer of Pacira. “By working collectively to develop, disseminate, and educate on these enhanced recovery protocols, and thus reducing exposure to debilitating and costly opioid-related adverse events or longer-term societal burden, we are truly advancing patient care.”
Beyond the unwanted and potentially life-threatening adverse events associated with opioid use, research continues to uncover the connection between their introduction in the hospital setting and the overall societal opioid burden.
A recent JAMA Internal Medicine article highlighted that for opioid-naive patients, many surgical procedures are associated with an increased risk of chronic opioid use in the postsurgical period;1 perhaps more startling, a recent national survey revealed that 1 in 10 patients admit they’ve become addicted to or dependent on opioids after being exposed to these powerful medications following an operation.2
Adding further validity to the importance and impact of these collaborative opioid-sparing protocols is the element of patient preference. A 2014 study uncovered that more than half of postsurgical patients prefer a non-opioid option,3 and a national survey conducted in 2016 found many patients have indicated they are delaying surgery due to fear of taking opioids to manage their pain.2
According to a 2016 analysis of health care claims, opioids also significantly contribute to health care system costs.4 The study showed that the national aggregated dollar value of charges related to opioid-related diagnoses increased more than 1,000 percent from 2011 ($32.4 million) to 2015 ($445.7 million), and private payers’ average costs for patients abusing or dependent on opioids was almost $16,000 more per patient than the average cost per patient across all patients’ claims.


By Ambiorix1